title: B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
abstract: In this study we aimed to investigate whether treatment with an immune modulatory drug had an effect on the distribution of B cell subpopulations in patients with remitting-relapsing multiple sclerosis (RRMS). We investigated the first-line drugs glatiramer acetate, interferon-β and natalizumab. Our data show that the frequency of the CD27(+)CD43(+) B1 cell subset was significantly diminished in RRMS patients compared to healthy subjects and that this subset was unaffected by treatment. Regardless of their true nature, we believe that these cells are part of the autoimmune disease pattern.
authors.affiliation: Department of Anatomy I, University Hospitals of Cologne, Joseph-Stelzman-Straße, 50931 Cologne, Germany; Department of Anatomy and Cell Biology, University of Wuerzburg, Koellikerstraße 6, 97070 Wuerzburg, Germany. Electronic address: damiano.rovituso@uni-wuerzburg.de.
authors.forename: Damiano
authors.initials: D
authors.lastname: Rovituso
authors.affiliation: Department of Anatomy I, University Hospitals of Cologne, Joseph-Stelzman-Straße, 50931 Cologne, Germany.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Heller
authors.affiliation: Department of Neurology, University Hospitals of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Schroeter
authors.affiliation: Department of Neurology, University Hospitals of Wuerzburg, Josef-Schneider-Str. 11, 97080 Wuerzburg, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Kleinschnitz
authors.affiliation: Department of Anatomy and Cell Biology, University of Wuerzburg, Koellikerstraße 6, 97070 Wuerzburg, Germany. Electronic address: stefanie.kuerten@uni-wuerzburg.de.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Kuerten
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D015703:Antigens, CD / Q000378:metabolism; D016175:B-Lymphocyte Subsets / Q000187:drug effects*; D005260:Female; D005434:Flow Cytometry; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000276:immunology / Q000473:pathology / Q000628:therapy; D000069442:Natalizumab; D010455:Peptides / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D007155:Immunologic Factors; D000069442:Natalizumab; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta
keywords: B cells; B1 cells; Flow cytometry; MS